Canadian Respiratory Journal / 2019 / Article / Tab 2

Research Article

Clinical Features and Contributing Factors of Excessive Daytime Sleepiness in Chinese Obstructive Sleep Apnea Patients: The Role of Comorbid Symptoms and Polysomnographic Variables

Table 2

Clinical manifestations and comorbidities of the total OSA patients and the patients with different severities of EDS.

TotalNon-EDSMild to moderate EDSSevere EDSχ2

Gasping/choking38.833.746.3c58.5a22.331<0.0001
Morning headache1712.423.3c36.9a,b33.529<0.0001
Dry mouth65.261.970.9c75.4a9.1220.010
Increased nocturia2825.429.147.7a,b14.5300.001
Memory loss61.255.370.5c81.5a28.023<0.0001
Irritability37.233.743.6c46.2a9.3200.009
Life disturbance38.833.047.1c61.5a,b29.075<0.0001
Work disturbance27.819.438.8c64.6a,b77.871<0.0001
Commute disturbance15.37.626.4c46.2a,b96.193<0.0001
Hypertension35.533.339.241.53.5920.166
T2DM9.37.012.3c18.5a12.4940.002
COPD451.83.14.5640.102
IHD9.89.39.316.93.9720.137
Stroke2.52.43.11.50.5800.748
Gastroesophageal reflux9.69.59.710.80.1190.942
Hypothyroidism3.34.01.83.12.4540.293
Pharyngitis43.644.540.546.21.2360.539
Rhinitis34.135.232.629.21.2400.538
Smoking9.49.68.89.20.1280.938
Alcohol use3.22.73.56.22.2870.319
History of upper airway surgery1.01.00.91.50.2140.898
Mandibular retraction5.65.37.03.11.7640.414
Tonsil enlargement9.27.213.2c12.37.9090.019
Pharyngeal stenosis16.412.422.5c30.8a22.815<0.0001

Data are presented as percentage. aComparisons between non-EDS versus severe EDS groups (); bcomparisons between mild to moderate EDS versus severe EDS groups (); ccomparisons between non-EDS versus mild to moderate EDS groups (). EDS: excessive daytime sleepiness; T2DM: type 2 diabetes mellitus; COPD: chronic obstructive pulmonary disease; IHD: ischemic heart disease.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.